IMR Press / FBE / Volume 2 / Issue 3 / DOI: 10.2741/E162

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Regulation of p53 isoform expression in renal cell carcinoma
Show Less
1 Institute of Pathology, Heinrich-Heine University Hospital, 40225 Duesseldorf, Germany
2 Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Hospital, 40225 Duesseldorf, Germany
3 Childrens Hospital Los Angeles, 4650 Sunset Blvd, Los Angeles, CA 90027, USA
Front. Biosci. (Elite Ed) 2010, 2(3), 1042–1053;
Published: 1 June 2010

Differential expression of p53 isoforms might participate in the marked resistance towards conventional chemotherapy of renal cell carcinomas (RCCs). Therefore, we analysed their differential expression and regulation in RCCs. RCCs expressed a more p53 activating isoform pattern during tumor initiation and progression, in vivo. In vitro, two cell lines exhibiting a similar sensitivity towards Topotecan-induced cell death revealed a similar induction of p53 target genes but strongly differed in their extent of apoptosis. Furthermore, they strongly differed in their basal expression patterns and differential regulation of the isoforms. In conclusion, our study examined for the first time the differential expression and regulation of all p53 isoforms in a tumor in vivo. Furthermore, novel results in our in vitro studies show that p53 isoforms are strongly differentially regulated by chemotherapy in RCCs and that expression and regulation of so-called "p53-target genes" are obviously at least in part regulated by other transcription factors. In addition, our original findings show that p53 isoform expression in RCC cell lines is of minor importance for sensitivity towards chemotherapy.

Back to top